401 related articles for article (PubMed ID: 16689015)
21. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression.
Prabha S; Labhasetwar V
Pharm Res; 2004 Feb; 21(2):354-64. PubMed ID: 15032319
[TBL] [Abstract][Full Text] [Related]
22. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems.
Luan X; Bodmeier R
J Control Release; 2006 Jan; 110(2):266-272. PubMed ID: 16300851
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: biodegradation.
Wu XS; Wang N
J Biomater Sci Polym Ed; 2001; 12(1):21-34. PubMed ID: 11334187
[TBL] [Abstract][Full Text] [Related]
24. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
[TBL] [Abstract][Full Text] [Related]
25. Clonazepam release from poly(DL-lactide-co-glycolide) nanoparticles prepared by dialysis method.
Nah JW; Paek YW; Jeong YI; Kim DW; Cho CS; Kim SH; Kim MY
Arch Pharm Res; 1998 Aug; 21(4):418-22. PubMed ID: 9875469
[TBL] [Abstract][Full Text] [Related]
26. Tuning the Size of Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticles Fabricated by Nanoprecipitation.
Huang W; Zhang C
Biotechnol J; 2018 Jan; 13(1):. PubMed ID: 28941234
[TBL] [Abstract][Full Text] [Related]
27. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content.
Budhian A; Siegel SJ; Winey KI
Int J Pharm; 2007 May; 336(2):367-75. PubMed ID: 17207944
[TBL] [Abstract][Full Text] [Related]
28. Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying.
Quaglia F; De Rosa G; Granata E; Ungaro F; Fattal E; Immacolata La Rotonda M
J Control Release; 2003 Jan; 86(2-3):267-78. PubMed ID: 12526823
[TBL] [Abstract][Full Text] [Related]
29. Bioresorbable nanofiber-based systems for wound healing and drug delivery: optimization of fabrication parameters.
Katti DS; Robinson KW; Ko FK; Laurencin CT
J Biomed Mater Res B Appl Biomater; 2004 Aug; 70(2):286-96. PubMed ID: 15264311
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.
Costantino L; Gandolfi F; Bossy-Nobs L; Tosi G; Gurny R; Rivasi F; Vandelli MA; Forni F
Biomaterials; 2006 Sep; 27(26):4635-45. PubMed ID: 16716395
[TBL] [Abstract][Full Text] [Related]
31. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.
Jain RA
Biomaterials; 2000 Dec; 21(23):2475-90. PubMed ID: 11055295
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid oligomers: Part II. Biodegradation and drug delivery application.
Wang N; Wu XS
J Biomater Sci Polym Ed; 1997; 9(1):75-87. PubMed ID: 9505204
[TBL] [Abstract][Full Text] [Related]
33. Design of amine-modified graft polyesters for effective gene delivery using DNA-loaded nanoparticles.
Oster CG; Wittmar M; Unger F; Barbu-Tudoran L; Schaper AK; Kissel T
Pharm Res; 2004 Jun; 21(6):927-31. PubMed ID: 15212155
[TBL] [Abstract][Full Text] [Related]
34. Production and surface modification of polylactide-based polymeric scaffolds for soft-tissue engineering.
Cao Y; Croll TI; Cooper-White JJ; O'Connor AJ; Stevens GW
Methods Mol Biol; 2004; 238():87-112. PubMed ID: 14970441
[No Abstract] [Full Text] [Related]
35. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA.
Dailey LA; Kleemann E; Wittmar M; Gessler T; Schmehl T; Roberts C; Seeger W; Kissel T
Pharm Res; 2003 Dec; 20(12):2011-20. PubMed ID: 14725368
[TBL] [Abstract][Full Text] [Related]
36. Optimized formulation of high-payload PLGA nanoparticles containing insulin-lauryl sulfate complex.
Shi K; Cui F; Yamamoto H; Kawashima Y
Drug Dev Ind Pharm; 2009 Feb; 35(2):177-84. PubMed ID: 19016099
[TBL] [Abstract][Full Text] [Related]
37. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone.
Teixeira M; Alonso MJ; Pinto MM; Barbosa CM
Eur J Pharm Biopharm; 2005 Apr; 59(3):491-500. PubMed ID: 15760730
[TBL] [Abstract][Full Text] [Related]
38. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release.
Yoo HS; Oh JE; Lee KH; Park TG
Pharm Res; 1999 Jul; 16(7):1114-8. PubMed ID: 10450940
[TBL] [Abstract][Full Text] [Related]
39. Preparation and characterization of Japanese encephalitis virus vaccine loaded poly(L-lactide-co-glycolide) microspheres for oral immunization.
Khang G; Cho JC; Lee JW; Rhee JM; Lee HB
Biomed Mater Eng; 1999; 9(1):49-59. PubMed ID: 10436853
[TBL] [Abstract][Full Text] [Related]
40. Nanocarriers with gentamicin to treat intracellular pathogens.
Lecaroz C; Gamazo C; Blanco-Prieto MJ
J Nanosci Nanotechnol; 2006; 6(9-10):3296-302. PubMed ID: 17048550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
